Although further studies are needed to test the renoprotective effect in other types of kidney disease, results from hypertension, FSGS and diabetes animal models22 support FHL2 inhibition could be a universal therapeutic strategy to treat glomerular diseases. Here, FHL2 is linked to focal segmental glomerulosclerosis.